Microbiome Global (FMT, Microbiome Drugs) Market Report 2022 Featuring Major Players – MicroBiome Therapeutics; Seres Therapeutics; Enterome Bioscience; Second Genome; Vedanta Biosciences – ResearchAndMarkets.com

Microbiome Global (FMT, Microbiome Drugs) Market Report 2022 Featuring Major Players – MicroBiome Therapeutics; Seres Therapeutics; Enterome Bioscience; Second Genome; Vedanta Biosciences – ResearchAndMarkets.com




Microbiome Global (FMT, Microbiome Drugs) Market Report 2022 Featuring Major Players – MicroBiome Therapeutics; Seres Therapeutics; Enterome Bioscience; Second Genome; Vedanta Biosciences – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Microbiome Global Market Report 2022: By Type, By Application, By Technology” report has been added to ResearchAndMarkets.com’s offering.

The global microbiome market is expected to grow from $5.54 billion in 2021 to $6.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.4%. The market is expected to reach $10.09 billion in 2026 at a CAGR of 13.1%.

The microbiome market consists of sales of microbiomes drugs and related services. Microbiome therapy aims at restoring balanced gut microbiota and is expected to decrease the risk of infection recurrence and greatly increase the quality of life of patients.

The main types of microbiomes are fecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation, or stool transplantation. The different technologies include genomics, proteomics, metabolomics and is used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, others.

The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn’s disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance.

These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. In 2019, approximately 1.6 million people in the United States suffered from untreatable inflammatory bowel disease (IBD), including Crohn’s or ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market.

The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market.

The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotica for both females and males.

The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier and oxidative stress.

In January 2021, Novozymes, a Denmark based biotechnology company acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a US-based probiotics company.

Major players in the microbiome market are

  • MicroBiome Therapeutics LLC
  • Seres Therapeutics
  • Enterome Bioscience
  • Second Genome
  • Vedanta Biosciences inc.
  • AbbVie inc.
  • Rebiotix, inc.
  • Ritter Pharmaceuticals
  • LNC Therapeutics inc.
  • ViThera Pharmaceuticals inc.
  • 4D Pharma plc.
  • Avid Biotics
  • AOBiome
  • Immuron Ltd.
  • Ganeden
  • Pfizer inc.
  • Bayer
  • Sigma-Tau Pharmaceuticals
  • Assembly Biosciences
  • Admera Health
  • Synthetic Biologics
  • AgBiome
  • APC Microbiome Institute
  • ActoGeniX
  • Azitra
  • Synlogic inc.
  • Evelo Biosciences
  • MaaT Pharma

Key Topics Covered:

1. Executive Summary

2. Microbiome Market Characteristics

3. Microbiome Market Trends And Strategies

4. Impact Of COVID-19 On Microbiome

5. Microbiome Market Size And Growth

5.1. Global Microbiome Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Microbiome Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Microbiome Market Segmentation

6.1. Global Microbiome Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Fecal Microbiota Transplantation (FMT)
  • Microbiome drugs

6.2. Global Microbiome Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Inflammatory Bowel Disease
  • Diabetes
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Others

6.3. Global Microbiome Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Genomics
  • Proteomics
  • Metabolomics

7. Microbiome Market Regional And Country Analysis

7.1. Global Microbiome Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Microbiome Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/q2bs8y

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900